Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A randomized, open label, phase III, multicenter trial

Andrén, Ove,1963-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Urology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden (author)

Cabazitaxel followed by androgen deprivation therapy (ADT) significantly improves time to progression in patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) : A randomized, open label, phase III, multicenter trial

Widmark, A.Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden (author)
Fält, A.Clinical Epidemiology and Biostatistics (author)
Ulvskog, E.,1963-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Oncology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)eug (author)
Davidsson, Sabina,1972-Örebro universitet,Institutionen för medicinska vetenskaper,Department of Urology, Faculty of Health and Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)sdn (author)
Karlsson, C. ThellenbergDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden (author)
Hjälm-Eriksson, M.Department of Oncology, Karolinska Institute, Stockholm, Sweden (author)
Örebro universitetInstitutionen för medicinska vetenskaper (creator_code:org_t)

By the author/editor: Andrén, Ove, 196 ...; Widmark, A.; Fält, A.; Ulvskog, E., 196 ...; Davidsson, Sabin ...; Karlsson, C. The ...; show more...; Hjälm-Eriksson, ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.